Abbott Laboratories (ABT)
NYSE · Healthcare · Medical Devices
$100.10+2.67%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $173B
- P/E (trailing)
- 32.3
- Forward P/E
- 16.5
- Dividend yield
- 2.5%
- 52-week range
- $81.97 – $135.24
- 52-week change
- −27.10%
- EPS (trailing)
- $3.10
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Oct 21, 2026
Fiscal year to Dec 2025
- Revenue
- $44.3B (+5.67%)
- Net income
- $6.5B
- Operating margin
- 18.2%
- Diluted EPS
- $3.72
- Free cash flow
- $7.4B
From the company’s annual report on SEC EDGAR.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Headquarters: Abbott Park, United States · 122,000 employees · abbott.com